BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15932563)

  • 1. Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence.
    Alexander-Sefre F; Chandrakumaran K; Banerjee S; Sexton R; Thomas JM; Moran B
    Colorectal Dis; 2005 Jul; 7(4):382-6. PubMed ID: 15932563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M
    Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated tumour markers are normalized in most patients with pseudomyxoma peritonei 7 days after complete tumour removal.
    Di Fabio F; Aston W; Mohamed F; Chandrakumaran K; Cecil T; Moran B
    Colorectal Dis; 2015 Aug; 17(8):698-703. PubMed ID: 25704482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: Analysis of 519 patients.
    Taflampas P; Dayal S; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
    Eur J Surg Oncol; 2014 May; 40(5):515-520. PubMed ID: 24462284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor markers: predictors of incomplete cytoreduction and powerful determinants of outcome in pseudomyxoma peritonei.
    Kusamura S; Hutanu I; Baratti D; Deraco M
    J Surg Oncol; 2013 Jul; 108(1):1-8. PubMed ID: 23720095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follow-up of patients treated by cytoreduction and chemotherapy for peritoneal carcinomatosis of colorectal origin.
    Verwaal VJ; Zoetmulder FA
    Eur J Surg Oncol; 2004 Apr; 30(3):280-5. PubMed ID: 15028309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
    Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced Pseudomyxoma Peritonei Requiring Gastrectomy to Achieve Complete Cytoreduction Results in Good Long-Term Oncologic Outcomes.
    Di Fabio F; Mehta A; Chandrakumaran K; Mohamed F; Cecil T; Moran B
    Ann Surg Oncol; 2016 Dec; 23(13):4316-4321. PubMed ID: 27380645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early recurrence of pseudomyxoma peritonei following treatment failure of cytoreductive surgery and perioperative intraperitoneal chemotherapy is indicative of a poor survival outcome.
    Chua TC; Liauw W; Morris DL
    Int J Colorectal Dis; 2012 Mar; 27(3):381-9. PubMed ID: 21853235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of CEA and CA 19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix.
    Carmignani CP; Hampton R; Sugarbaker CE; Chang D; Sugarbaker PH
    J Surg Oncol; 2004 Sep; 87(4):162-6. PubMed ID: 15334630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy.
    Baratti D; Kusamura S; Nonaka D; Cabras AD; Laterza B; Deraco M
    Ann Surg; 2009 Feb; 249(2):243-9. PubMed ID: 19212177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer.
    Takagawa R; Fujii S; Ohta M; Nagano Y; Kunisaki C; Yamagishi S; Osada S; Ichikawa Y; Shimada H
    Ann Surg Oncol; 2008 Dec; 15(12):3433-9. PubMed ID: 18846401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
    Lai IR; Lee WJ; Huang MT; Lin HH
    Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei--a report of 103 procedures.
    Smeenk RM; Verwaal VJ; Zoetmulder FA
    Eur J Surg Oncol; 2006 Mar; 32(2):186-90. PubMed ID: 16303281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carcinoembryonic antigen (CEA) measurement during follow-up for rectal carcinoma is useful even if normal levels exist before surgery. A retrospective study of CEA values in the TME trial.
    Grossmann I; de Bock GH; Meershoek-Klein Kranenbarg WM; van de Velde CJ; Wiggers T
    Eur J Surg Oncol; 2007 Mar; 33(2):183-7. PubMed ID: 17174516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Italian Multicentric Phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with pseudomyxoma peritonei.
    Deraco M; De Simone M; Rossi CR; Cavaliere F; Di Filippo F; Vaira M; Piatti P; Kusamura S
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):35-9. PubMed ID: 16767904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreduction including total gastrectomy for pseudomyxoma peritonei.
    Sugarbaker PH
    Br J Surg; 2002 Feb; 89(2):208-12. PubMed ID: 11856136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of elevated tumor markers in patients with disseminated appendiceal malignancies treated by cytoreductive surgery and HIPEC.
    Ross A; Sardi A; Nieroda C; Merriman B; Gushchin V
    Eur J Surg Oncol; 2010 Aug; 36(8):772-6. PubMed ID: 20561764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early prediction of tumor recurrence after curative resection of gastric carcinoma by measuring soluble E-cadherin.
    Chan AO; Chu KM; Lam SK; Cheung KL; Law S; Kwok KF; Wong WM; Yuen MF; Wong BC
    Cancer; 2005 Aug; 104(4):740-6. PubMed ID: 15991243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.